At least 14 immunotherapeutics or vaccines against beta amyloid are in clinical development to treat Alzheimer's disease (AD). Three Phase III antibodies that are thought to neutralize beta amyloid are expected to yield data in 2013. Source: BCIQ: BioCentury Online Intelligence

Company

Product

Description

Status

Baxter International Inc. (NYSE:BAX)

Gammagard Liquid 10%

Plasma-based therapy containing IgG antibodies

Ph III